AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Receives Buy Rating from Jefferies Group LLC

Jefferies Group LLC reaffirmed their buy rating on shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in a research report sent to investors on Sunday, November 5th. They currently have a $16.00 price target on the specialty pharmaceutical company’s stock.

A number of other research analysts also recently commented on AMAG. BidaskClub downgraded AMAG Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, August 10th. Cowen Inc restated a hold rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Cantor Fitzgerald restated a hold rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Janney Montgomery Scott reiterated a hold rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Finally, Morgan Stanley decreased their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an overweight rating for the company in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $24.00.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.45 during trading hours on Friday, reaching $14.20. The company had a trading volume of 252,635 shares, compared to its average volume of 1,109,468. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $36.83. The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.

WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://baseballnewssource.com/markets/amag-pharmaceuticals-inc-amag-stock-rating-reaffirmed-by-jefferies-group-llc/1760330.html.

Several institutional investors and hedge funds have recently modified their holdings of AMAG. Karp Capital Management Corp bought a new stake in AMAG Pharmaceuticals during the 1st quarter worth approximately $232,000. OppenheimerFunds Inc. grew its position in AMAG Pharmaceuticals by 101.1% during the 1st quarter. OppenheimerFunds Inc. now owns 17,575 shares of the specialty pharmaceutical company’s stock worth $396,000 after acquiring an additional 8,836 shares during the last quarter. Principal Financial Group Inc. grew its position in AMAG Pharmaceuticals by 1.6% during the 1st quarter. Principal Financial Group Inc. now owns 261,929 shares of the specialty pharmaceutical company’s stock worth $5,906,000 after acquiring an additional 4,008 shares during the last quarter. Wellington Management Group LLP grew its position in AMAG Pharmaceuticals by 233.5% during the 1st quarter. Wellington Management Group LLP now owns 161,739 shares of the specialty pharmaceutical company’s stock worth $3,648,000 after acquiring an additional 113,240 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in AMAG Pharmaceuticals by 3.6% during the 1st quarter. Teachers Advisors LLC now owns 62,055 shares of the specialty pharmaceutical company’s stock worth $1,399,000 after acquiring an additional 2,164 shares during the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.